Randomised Clinical Trial
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study
Version of Record online: 5 FEB 2013
© 2013 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 6, pages 604–612, March 2013
How to Cite
Aliment Pharmacol Ther 2013; 37: 604–612
- Issue online: 14 FEB 2013
- Version of Record online: 5 FEB 2013
- Accepted manuscript online: 5 FEB 2013 12:00AM EST
- Manuscript Accepted: 14 JAN 2013
- Manuscript Revised: 10 JAN 2013
- Manuscript Revised: 24 DEC 2012
- Manuscript Received: 17 NOV 2012
- PSC Partners
Table S1. Number of patients who experienced side effects from study drugs. (a) Vancomycin groups, (b) Metronidazole groups.
Figure S1. Change in total bilirubin in low- and high-dose vancomycin and metronidazole groups
Figure S2. Change in Mayo PSC risk score in low- and high-dose vancomycin and metronidazole groups
Figure S3. Difference between baseline and 12-week pruritus VAS score for individuals in each study group.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.